Literature DB >> 26334317

Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.

Xingfu Wang1, Yupeng Chen2, Sheng Zhang3, Lifeng Zhang4, Xueyong Liu5, Li Zhang6, Xiaoling Li7, Dayang Chen8.   

Abstract

Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) are important factors in tumorigenesis and malignant progression; however, studies of their roles in glioblastoma have produced conflicting results. To define the frequencies of COX-2 and 5-LO expression and their correlation with clinicopathological features and prognosis, tumor tissues from 76 cases of newly diagnosed primary ordinary glioblastoma were examined for COX-2 and 5-LO expression by immunohistochemistry. The expression levels of COX-2 and 5-LO and the relationships between the co-expression of COX-2/5-LO and patient age and gender, edema index (EI), Karnofsky Performance Scale and overall survival (OS) were analyzed. COX-2 and 5-LO were expressed in 73.7 % (56/76) and 92.1 % (70/76) of the samples, respectively. Among the clinicopathological characteristics, only age (>60 years) exhibited a significant association with the high expression of COX-2. No statistically significant correlations were found in the 5-LO cohort. A significant positive correlation was revealed between the COX-2 and 5-LO scores (r = 0.374; p = 0.001). The elevated co-expression of COX-2 and 5-LO was observed primarily in the patients over the age of 60 years. Patients with a high expression of COX-2 had a significantly shorter OS (p < 0.01), whereas the immunoexpression of 5-LO was not associated with the OS of patients with glioblastoma. Survival analysis indicated that simultaneous high levels of COX-2 and 5-LO expression were significantly correlated with poor OS and, conversely, that a low/low expression pattern of these two proteins was significantly associated with better OS (p < 0.05). Moreover, the Cox multivariable proportional hazard model showed that a high expression of COX-2, high co-expression of COX-2 and 5-LO, and a high Ki-67 index were significant predictors of shorter OS in primary glioblastoma, independent of age, gender, EI, 5-LO expression and p53 status. The hazard ratios for OS were 2.347 (95 % CI 1.30-4.25, p = 0.005), 1.900 (95 % CI 1.30-2.78, p = 0.001), and 2.210 (95 % CI 1.19-4.09, p = 0.011), respectively. These results suggest that COX-2 and 5-LO play roles in tumorigenesis and the progression of primary glioblastoma and that the co-expression pattern of COX-2/5-LO may be used as an independent prognostic factor in this disease.

Entities:  

Keywords:  5-LO; COX-2; Glioblastoma; Immunohistochemistry; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26334317     DOI: 10.1007/s11060-015-1919-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  43 in total

1.  Increased expression of 5-lipoxygenase in glioblastoma multiforme.

Authors:  Mladen Golubic; Richard A Prayson; Linda Vargo; Judy Bondar; Gene H Barnett
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

Review 2.  Cyclooxygenases and lipoxygenases in cancer.

Authors:  Claus Schneider; Ambra Pozzi
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 3.  Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.

Authors:  Jayson I L Bastien; Katharine A McNeill; Howard A Fine
Journal:  Cancer       Date:  2014-09-23       Impact factor: 6.860

4.  The impact of cyclooxygenase-2 and vascular endothelial growth factor C immunoexpression on the prognosis of penile carcinoma.

Authors:  Adriano Augusto Peclat De Paula; Eliane Duarte Motta; Rita de Cassia Alencar; Vera Aparecida Saddi; Rosana Correa da Silva; Gustavo Nogueira Caixeta; Joaquim Caetano Almeida Netto; Megmar Aparecida dos Santos Carneiro
Journal:  J Urol       Date:  2011-11-16       Impact factor: 7.450

5.  Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma.

Authors:  Lei Zhang; Wei-Ping Zhang; Hua Hu; Meng-Ling Wang; Wen-Wen Sheng; Hong-Tian Yao; Wei Ding; Zhong Chen; Er-Qing Wei
Journal:  Neuropathology       Date:  2006-04       Impact factor: 1.906

6.  Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo.

Authors:  M H Deininger; M Weller; J Streffer; M Mittelbronn; R Meyermann
Journal:  Acta Neuropathol       Date:  1999-09       Impact factor: 17.088

7.  Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival.

Authors:  Marina Perdiki; Penelope Korkolopoulou; Irene Thymara; George Agrogiannis; Christina Piperi; Efstathios Boviatsis; Xenophon Kotsiakis; Dimitrios Angelidakis; Kalliopi Diamantopoulou; Euphemia Thomas-Tsagli; Efstratios Patsouris
Journal:  Mol Cell Biochem       Date:  2006-07-26       Impact factor: 3.396

8.  Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.

Authors:  Xiaoling Ding; Chen Zhu; Hui Qiang; Xiaorong Zhou; Guoxiong Zhou
Journal:  Biomed Pharmacother       Date:  2011-08-27       Impact factor: 6.529

9.  Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma.

Authors:  H Takatori; S Natsugoe; H Okumura; M Matsumoto; Y Uchikado; T Setoyama; K Sasaki; K Tamotsu; T Owaki; S Ishigami; T Aikou
Journal:  Eur J Surg Oncol       Date:  2007-06-05       Impact factor: 4.424

Review 10.  The eicosanoid cascade: possible role in gliomas and meningiomas.

Authors:  N Nathoo; G H Barnett; M Golubic
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

View more
  3 in total

1.  Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma.

Authors:  Huajie Liu; Bin Liu; Xianzeng Hou; Bo Pang; Pengbo Guo; Wanli Jiang; Qian Ding; Rui Zhang; Tao Xin; Hua Guo; Shangchen Xu; Qi Pang
Journal:  J Neurooncol       Date:  2017-03-21       Impact factor: 4.130

2.  The 1,4 benzoquinone-featured 5-lipoxygenase inhibitor RF-Id induces apoptotic death through downregulation of IAPs in human glioblastoma cells.

Authors:  S Zappavigna; M Scuotto; A M Cossu; D Ingrosso; M De Rosa; C Schiraldi; R Filosa; M Caraglia
Journal:  J Exp Clin Cancer Res       Date:  2016-10-22

3.  Kukoamine A inhibits human glioblastoma cell growth and migration through apoptosis induction and epithelial-mesenchymal transition attenuation.

Authors:  Qiaoping Wang; Haiyan Li; Zhen Sun; Lihua Dong; Ling Gao; Chunlan Liu; Xiujie Wang
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.